These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 12796135)
1. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Silvestri A; Gebara O; Vitale C; Wajngarten M; Leonardo F; Ramires JA; Fini M; Mercuro G; Rosano GM Circulation; 2003 Jul; 107(25):3165-9. PubMed ID: 12796135 [TBL] [Abstract][Full Text] [Related]
2. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. Eilertsen AL; Høibraaten E; Os I; Andersen TO; Sandvik L; Sandset PM Maturitas; 2005 Oct; 52(2):111-8. PubMed ID: 16186073 [TBL] [Abstract][Full Text] [Related]
3. Effects of hormone therapy on soluble cell adhesion molecules in postmenopausal women with coronary artery disease. Yeboah J; Klein K; Brosnihan B; Reboussin D; Herrington DM Menopause; 2008; 15(6):1060-4. PubMed ID: 18521047 [TBL] [Abstract][Full Text] [Related]
4. Value of C-reactive protein levels and IL-6 in predicting events levels in women at increased cardiovascular risk. Vitale C; Gebara O; Mercuro G; Wajngarten M; Silvestri A; Rossini P; Ramires JA; Fini M; Rosano GM Maturitas; 2005 Apr; 50(4):239-46. PubMed ID: 15780522 [TBL] [Abstract][Full Text] [Related]
5. Genetic variation in estrogen receptor, C-reactive protein and fibrinogen does not predict the plasma levels of inflammation markers after longterm hormone replacement therapy. de Maat MP; Madsen JS; Langdahl B; Bladbjerg EM; Tofteng CL; Abrahamsen B; Rejnmark L; Brixen K; Christensen K; Jespersen J; Kristensen SR Thromb Haemost; 2007 Feb; 97(2):234-9. PubMed ID: 17264952 [TBL] [Abstract][Full Text] [Related]
6. High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol. Blumenfeld Z; Boulman N; Leiba R; Siegler E; Shachar S; Linn R; Levy Y Scand J Clin Lab Invest; 2007; 67(3):257-63. PubMed ID: 17454839 [TBL] [Abstract][Full Text] [Related]
7. Effects of hormone therapy on C-reactive protein and IL-6 in postmenopausal women: a review article. Lakoski SG; Herrington DM Climacteric; 2005 Dec; 8(4):317-26. PubMed ID: 16390766 [TBL] [Abstract][Full Text] [Related]
8. Effect of transdermal hormone replacement therapy on the monocyte chemoattractant protein-1 concentrations and other vascular inflammatory markers and on endothelial function in postmenopausal women. Sumino H; Ichikawa S; Ohyama Y; Takahashi T; Saito Y; Nakamura T; Kanda T; Kurabayashi M Am J Cardiol; 2005 Jul; 96(1):148-53. PubMed ID: 15979455 [TBL] [Abstract][Full Text] [Related]
9. No increase in C-reactive protein levels during intranasal compared to oral hormone therapy in healthy post-menopausal women. Hemelaar M; Kenemans P; Schalkwijk CG; Braat DD; van der Mooren MJ Hum Reprod; 2006 Jun; 21(6):1635-42. PubMed ID: 16501036 [TBL] [Abstract][Full Text] [Related]
10. Effects of hormone replacement therapy on glucose and lipid profiles and on cardiovascular risk parameters in postmenopausal women. Bingol B; Gunenc Z; Yilmaz M; Biri A; Tiras B; Güner H Arch Gynecol Obstet; 2010 May; 281(5):857-64. PubMed ID: 19593578 [TBL] [Abstract][Full Text] [Related]
11. Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. Gol M; Akan P; Dogan E; Karas C; Saygili U; Posaci C Maturitas; 2006 Feb; 53(3):252-9. PubMed ID: 15990257 [TBL] [Abstract][Full Text] [Related]
12. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. Ho JY; Chen MJ; Sheu WH; Yi YC; Tsai AC; Guu HF; Ho ES Hum Reprod; 2006 Oct; 21(10):2715-20. PubMed ID: 16807281 [TBL] [Abstract][Full Text] [Related]
13. Effect of vitamin E supplementation with and without hormone therapy on circulatory inflammatory markers in postmenopausal women. Carr BR; Khan N; Adams-Huet B; Kakarla N; Havelock JC; Gell J Fertil Steril; 2006 Mar; 85(3):667-73. PubMed ID: 16500336 [TBL] [Abstract][Full Text] [Related]
14. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Diamanti-Kandarakis E; Paterakis T; Alexandraki K; Piperi C; Aessopos A; Katsikis I; Katsilambros N; Kreatsas G; Panidis D Hum Reprod; 2006 Jun; 21(6):1426-31. PubMed ID: 16497699 [TBL] [Abstract][Full Text] [Related]
15. Effect of hormone replacement therapy on inflammation-sensitive proteins in post-menopausal women with Type 2 diabetes. Manning PJ; Sutherland WH; Allum AR; de Jong SA; Jones SD Diabet Med; 2002 Oct; 19(10):847-52. PubMed ID: 12358873 [TBL] [Abstract][Full Text] [Related]
16. Changes in inflammatory biomarkers following one-year of moderate resistance training in overweight women. Olson TP; Dengel DR; Leon AS; Schmitz KH Int J Obes (Lond); 2007 Jun; 31(6):996-1003. PubMed ID: 17299382 [TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy. Vitale C; Cornoldi A; Gebara O; Silvestri A; Wajngarten M; Cerquetani E; Fini M; Ramires JA; Rosano GM Menopause; 2005; 12(5):552-8. PubMed ID: 16145309 [TBL] [Abstract][Full Text] [Related]